Dr. Arrow comes to lead Zelegent, Inc. from Biolase, Inc. (NASDAQ: BIOL), the world’s lead manufacturer of dental lasers, where he served as a President and Chief Operating Officer, a Director, and Chair of the Audit and Compensation committees of the Board of Directors. Prior to Biolase, Dr. Arrow was the Chief Medical Officer of Stanford-affiliated neuroscience company Circuit Therapeutics, Inc., and prior to that he spent five years as the Chief Financial Officer of cardiovascular device manufacturer Arstasis, Inc. As CFO of Arstasis, he worked with future Zelegent VP of Regulatory and Clinical Affairs David Humbert, and future Zelegent VP of Engineering Joe Paraschac.
Before entering medical device manufacturer operating roles, Dr. Arrow spent nine years running medical technology equity research at three Wall Street firms, the last five years at Lazard. He also served as the Chief Financial Officer of the Patent & License Exchange, Inc. He has an MD from Harvard Medical School and began his surgical residency at the UCLA Medical Center before leaving to go into business.
David Humbert, RAC
Vice President of Regulatory and Clinical Affairs
David Humbert brings over twenty-five years of medical device regulatory experience to Zelegent, Inc., including managing successful approval applications of both active implantable devices like the WorldHeart left ventricular assist system, and minimally-invasive devices similar to Zelegent’s new tool. He first met Dr. Arrow when he was brought in to cardiovascular device manufacturer Arstasis, Inc. to manage the 510(k) submission process for that company’s minimally-invasive access device.
Mr. Humbert’s career has included directing the regulatory efforts at Emphasys Medical and Arstasis, Inc. from 2007-2009, and supporting several Class III medical device submission projects for Oxford International and Black Diamond Networks, from 2009-2014. He was Director of Regulatory Affairs at WorldHeart, Inc. from 2001-2007, a Corporate Consultant to the Regulatory Affairs group at Boston Scientific from 1997-2001, and supported the broad Regulatory Affairs function at Guidant Corporation’s Devices for Vascular Intervention, Inc. from 1990-1994. He was one of the first 500 regulatory professionals in the U.S. to earn the Regulatory Affairs Certified (RAC) credential in 1993.
Director of Engineering
Rick Lilly brings 19 years of medical device engineering experience to Zelegent, with a career that has focused on bio-resorbable, implantable medical devices, like the Elevo implant. Prior to Zelegent, Rick spent three years as the Director of R&D for Articulinx, Inc., a company developing a small joint flexibility implant. Prior to Articulinx, he spent four years as the R&D Engineering Manager for Transcend Medical Inc., in which he brought the inserter for the company’s Ophthalmology device from concept to clinic in just four months. Prior to Transcend, Rick was the R&D Program Manager at Apneon Inc., a company developing a complex implantable anti-snoring device, where he took over for Joseph Paraschac. Rick similarly succeeds Joe Paraschac at Zelegent: Joe was the engineer who refined the Elevo implant design before Rick, and one of the most prolific inventors in the field of sleep apnea and suture handling.
Rick is a named inventor on 11 issued medical device U.S. patents, including sutureless vessel plugs and ocular implantables, and holds a BSME degree from California Polytechnic State University.
CAUTION — Investigational device. Limited by Federal (or United States) law to investigational use.